Bladder cancer remains one of the most common and expensive cancers to treat worldwide. Numerous molecular markers are being investigated as possible ways to decrease health care costs, increase patient survival and prognosis, and increase sensitivity in screening tests. Several genetic markers have emerged as potential therapeutic targets and have provided new theories concerning the origins and progression of these tumors. Future classifications of bladder tumors should be based on the understanding of disease processes and should incorporate these emerging biomarkers for stratification of tumors into different prognostic groups.
|Original language||English (US)|
|Number of pages||12|
|Journal||Analytical and Quantitative Cytology and Histology|
|State||Published - Feb 1 2009|
- Bladder cancer
- Molecular genetics
ASJC Scopus subject areas